FDA Approves Moderna's mRNA Flu Vaccine Despite Political Turbulence

The Food and Drug Administration has granted its first-ever approval for a flu vaccine using mRNA technology, marking a significant milestone in immunization science even as the regulatory path proved unexpectedly fraught with political obstacles.

The Approval#

Moderna announced Thursday that its shot, mFLUSIVA (mRNA-1010), won authorization for all adults aged 50 and older. The green light followed a June vote by FDA advisory panelists who unanimously backed the vaccine's clearance, citing its superior performance against seasonal flu compared to conventional shots and a solid safety profile from trials involving nearly 44,000 participants.

Political Headwinds#

The road to approval, however, was fraught with unexpected challenges from within the Trump administration. Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, has used his position to obstruct vaccination efforts—including canceling a federally-funded flu vaccination campaign during an active flu season that was affecting children at unusually high rates. Kennedy has been similarly dismissive of mRNA vaccines, calling the COVID-19 shot "the deadliest vaccine ever made" and terminating hundreds of millions in federal mRNA research funding.

The Regulatory Stumble and Recovery#

The vaccine's review hit a major snag in February when Vinay Prasad, a Trump-appointed FDA official and Kennedy ally, abruptly refused to even consider Moderna's application, contradicting FDA career staff and shocking the biomedical research community. Prasad justified the rejection by claiming Moderna had chosen the wrong comparator vaccine for its trials—a position FDA officials themselves had previously endorsed during the study design phase. Moderna contested this, and the agency reversed course within days. Prasad subsequently departed the FDA in late April following a series of contentious regulatory decisions that drew widespread criticism.